KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Liabilities (2016 - 2025)

Vertex Pharmaceuticals has reported Total Liabilities over the past 17 years, most recently at $7.0 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $7.0 billion for Q4 2025, up 13.94% from a year ago — trailing twelve months through Dec 2025 was $7.0 billion (up 13.94% YoY), and the annual figure for FY2025 was $7.0 billion, up 13.94%.
  • Total Liabilities for Q4 2025 was $7.0 billion at Vertex Pharmaceuticals, down from $7.5 billion in the prior quarter.
  • Over the last five years, Total Liabilities for VRTX hit a ceiling of $7.5 billion in Q3 2025 and a floor of $3.0 billion in Q2 2021.
  • Median Total Liabilities over the past 5 years was $5.0 billion (2023), compared with a mean of $4.9 billion.
  • Biggest five-year swings in Total Liabilities: decreased 2.53% in 2021 and later skyrocketed 41.79% in 2023.
  • Vertex Pharmaceuticals' Total Liabilities stood at $3.3 billion in 2021, then grew by 27.18% to $4.2 billion in 2022, then increased by 21.51% to $5.1 billion in 2023, then rose by 18.91% to $6.1 billion in 2024, then rose by 13.94% to $7.0 billion in 2025.
  • The last three reported values for Total Liabilities were $7.0 billion (Q4 2025), $7.5 billion (Q3 2025), and $6.9 billion (Q2 2025) per Business Quant data.